SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

PDS Biotechnology Corp
Date: May 30, 2025 · CIK: 0001472091 · Accession: 0000000000-25-005744

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-287588

Date
May 30, 2025
Author
Division of
Form
UPLOAD
Company
PDS Biotechnology Corp

Letter

Re: PDS Biotechnology Corporation Registration Statement on Form S-3 Filed May 27, 2025 File No. 333-287588 Dear Frank Bedu-Addo:

May 30, 2025

Frank Bedu-Addo President and Chief Executive Officer PDS Biotechnology Corporation 303A College Road East Princeton, NJ 08540

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Alan Campbell at 202-551-4224 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Patrick O Malley, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 May 30, 2025

Frank Bedu-Addo
President and Chief Executive Officer
PDS Biotechnology Corporation
303A College Road East
Princeton, NJ 08540

 Re: PDS Biotechnology Corporation
 Registration Statement on Form S-3
 Filed May 27, 2025
 File No. 333-287588
Dear Frank Bedu-Addo:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Alan Campbell at 202-551-4224 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Patrick O Malley, Esq.
</TEXT>
</DOCUMENT>